352 related articles for article (PubMed ID: 30483483)
1. Cellular Targets for the Treatment of Flavivirus Infections.
Zakaria MK; Carletti T; Marcello A
Front Cell Infect Microbiol; 2018; 8():398. PubMed ID: 30483483
[TBL] [Abstract][Full Text] [Related]
2. The importance of viral and cellular factors on flavivirus entry.
Cordero-Rivera CD; De Jesús-González LA; Osuna-Ramos JF; Palacios-Rápalo SN; Farfan-Morales CN; Reyes-Ruiz JM; Del Ángel RM
Curr Opin Virol; 2021 Aug; 49():164-175. PubMed ID: 34171540
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.
de Wispelaere M; Lian W; Potisopon S; Li PC; Jang J; Ficarro SB; Clark MJ; Zhu X; Kaplan JB; Pitts JD; Wales TE; Wang J; Engen JR; Marto JA; Gray NS; Yang PL
Cell Chem Biol; 2018 Aug; 25(8):1006-1016.e8. PubMed ID: 29937406
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in flavivirus antiviral drug discovery and vaccine development.
Ray D; Shi PY
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):45-55. PubMed ID: 18221133
[TBL] [Abstract][Full Text] [Related]
5. Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.
Li PC; Jang J; Hsia CY; Groomes PV; Lian W; de Wispelaere M; Pitts JD; Wang J; Kwiatkowski N; Gray NS; Yang PL
ACS Infect Dis; 2019 Mar; 5(3):460-472. PubMed ID: 30608640
[TBL] [Abstract][Full Text] [Related]
6. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
7. The science of direct-acting antiviral and host-targeted agent therapy.
Pawlotsky JM
Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
[TBL] [Abstract][Full Text] [Related]
8. Beyond the Surface: Endocytosis of Mosquito-Borne Flaviviruses.
Carro SD; Cherry S
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374822
[TBL] [Abstract][Full Text] [Related]
9. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs.
Pastorino B; Nougairède A; Wurtz N; Gould E; de Lamballerie X
Antiviral Res; 2010 Sep; 87(3):281-94. PubMed ID: 20452379
[TBL] [Abstract][Full Text] [Related]
10. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
von Hahn T; Ciesek S; Manns MP
Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851
[TBL] [Abstract][Full Text] [Related]
11. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection.
Lee SM; Yen HL
Antiviral Res; 2012 Dec; 96(3):391-404. PubMed ID: 23022351
[TBL] [Abstract][Full Text] [Related]
12. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
13. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
Behrendt P; Perin P; Menzel N; Banda D; Pfaender S; Alves MP; Thiel V; Meuleman P; Colpitts CC; Schang LM; Vondran FWR; Anggakusuma ; Manns MP; Steinmann E; Pietschmann T
Antiviral Res; 2017 Nov; 147():19-28. PubMed ID: 28923507
[TBL] [Abstract][Full Text] [Related]
14. Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.
Mitra B; Thapa RJ; Guo H; Block TM
Antiviral Res; 2018 Oct; 158():185-198. PubMed ID: 30145242
[TBL] [Abstract][Full Text] [Related]
15. The flavivirus capsid protein: Structure, function and perspectives towards drug design.
Oliveira ERA; Mohana-Borges R; de Alencastro RB; Horta BAC
Virus Res; 2017 Jan; 227():115-123. PubMed ID: 27751882
[TBL] [Abstract][Full Text] [Related]
16. Discovery of host-targeted covalent inhibitors of dengue virus.
de Wispelaere M; Carocci M; Liang Y; Liu Q; Sun E; Vetter ML; Wang J; Gray NS; Yang PL
Antiviral Res; 2017 Mar; 139():171-179. PubMed ID: 28034743
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
18. The interactions of flaviviruses with cellular receptors: Implications for virus entry.
Anwar MN; Akhtar R; Abid M; Khan SA; Rehman ZU; Tayyub M; Malik MI; Shahzad MK; Mubeen H; Qadir MS; Hameed M; Wahaab A; Li Z; Liu K; Li B; Qiu Y; Ma Z; Wei J
Virology; 2022 Mar; 568():77-85. PubMed ID: 35149346
[TBL] [Abstract][Full Text] [Related]
19. Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice.
Segura Guerrero NA; Sharma S; Neyts J; Kaptein SJF
Antiviral Res; 2018 Dec; 160():137-142. PubMed ID: 30385306
[TBL] [Abstract][Full Text] [Related]
20. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
